This study underscores the role of IgM antibodies in combating Brucella infection, offers insights for antibody-based immunotherapy, and provides a theoretical foundation for developing multi-epitope vaccines based on the conserved epitopes and critical residues.
Abstract
Background
Brucellosis, a severe zoonotic infectious disease, poses substantial economic and health threats globally. The intracellular survival strategy of Brucella complicates disease control, highlighting the need for novel immunotherapeutic strategies such as antibody-based therapies and multi-epitope vaccines.
Results
This study generated two IgM monoclonal antibodies (D3 and F5) against the conserved outer membrane protein OMP16 of Brucella using hybridoma technology. Peptide scanning and Western blot identified their linear epitopes (D3: 77TLSKQAQW84; F5: 120RDFLASRG127), which are highly conserved among major Brucella species. Integrated approaches-including molecular docking, alanine-scanning mutagenesis, and dot-blot assays-revealed key residues at the epitope interface that form stable bonds with antibody complementarity-determining regions (CDRs). Functionally, both antibodies activated the complement system, with F5 exhibiting significant complement-dependent bacteriolytic activity in vitro. Furthermore, in the presence of complement, D3 and F5 enhanced macrophage-mediated opsonophagocytosis and intracellular killing of Brucella abortus A19. In a mouse infection model, passive immunization with either antibody significantly alleviated infection-induced weight loss and splenomegaly and reduced bacterial load in the spleen.
Conclusions
Our study underscores the role of IgM antibodies in combating Brucella infection, offers insights for antibody-based immunotherapy, and provides a theoretical foundation for developing multi-epitope vaccines based on the conserved epitopes and critical residues.
This study developed BP26-OMP16Es, a self-assembling nanoparticle vaccine constructed by fusing immunodominant B- and T-cell epitopes from OMP16 to the self-assembling antigen BP26 via flexible linkers, yielding single-copy and double-copy epitope tandem nanoparticles.
Yun-Yi Zhai, Kai-Hui Sun, G. WuDong et al.· ACS Nano· 0 citations
Through multi-omics integration analysis, this study successfully identified a novel candidate antigen, BMEI1943, with strong Th1-type immunogenicity, providing an experimental basis for the development of safe and efficient subunit vaccines against brucellosis.
Zhi-Heng Dong, Sha Li, Jiarong Guo et al.· Brazilian Journal of Microbi...· 0 citations
The development of a multi-epitope messenger RNA (mRNA) vaccine candidate targeting Brucella melitensis, the most pathogenic species responsible for human brucellosis is reported, establishing a promising platform for Brucella vaccine development warranting further evaluation in large animal models and human clinical t...
Zhi-Heng Dong, Sha Li, Jiarong Guo et al.· Research in Veterinary Scien...· 0 citations
Human tularemia is caused by infection with the intracellular bacterium Francisella tularensis. The ability of the bacterium to cause a severe pneumonic form of the disease has led to concerns in the field of biodefense and efforts to develop a vaccine. F. tularensis LVS provides partial protection against fully virule...
Pavlina Laskova, S. Porkertova, O. Ballek et al.· PLoS Pathogens· 0 citations
The rationally designed multi-epitope vaccine demonstrates robust theoretical potential to elicit comprehensive, long-lasting immunity in humans, although its safety and effectiveness require additional experimental validation.
Chenchen Yi, Yu Shen, Ye Luo et al.· Frontiers in Cellular and In...· 0 citations
This study identifies a novel, highly conserved with conservative substitutions linear B-cell epitope on the RABV glycoprotein, providing a precise molecular target for the rational design of next-generation epitope-based vaccines and specific diagnostic tools.
Yu-Mei Chen, Xiao-Hui Zhang, Yan-Hua Qi et al.· Medical Microbiology and Imm...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.